HIV¸ÐȾ£¬ÎªÊ²Ã´³öÏÖÑÛ²¿Ö¢×´£¿

°¬×̲¡ 2023-06-03 17:41°¬×̲¡Ö¢×´www.xingbingw.cn

¸ßЧ¿¹Äæ×ªÂ¼ÖÎÁÆ£¨HAART£©ÄÜÊ®·ÖÓÐЧ¿ØÖÆHIV¸ÐȾ£¬´ó´óÌá***IV¸ÐȾÕßµÄÉú´æÂÊ£¬µ«ÖÎÁƹý³ÌÖдøÀ´µÄ¶¾¸±×÷Óü°Ïà¹Ø»ú»áÐÔ¸ÐȾÈÔÊÇÎÞ·¨È«Êý±ÜÃâµÄ¡£HIVÑÛ²¿²¡±ä·¢Õ¹ÒþÄ䣬ÁÙ´²±íÏÖ¸÷²»Ïàͬ£¬¿É·¢ÉúÔÚ´ó¶àÊýHIV¸ÐȾÕߺÍAIDS»¼ÕßÖС£µ½µ×HIV¸ÐȾ¸úÑÛ²¿²¡±äÖ®¼äÓÐʲô¹ØÁª£¿

1 HIVÓëÑÛ²¿Ö¢×´µÄÁªÏµ

HIV×÷Ϊһ¸öÖ÷ÒªÇÖ·¸ÃâÒßϵͳµÄ¼²²¡£¬¶ÔÑÛ¾¦ÓÖÓÐʲôӰÏìÄØ£¿

Ò»Ïî2012ÄêÔÚÓ¡¶È¿ªÕ¹µÄÑо¿¶ÔHIV/AIDS²¡ÀýµÄÑÛ²¿Ö¢×´½øÐÐÁ˺á¶ÏÃæÑо¿¡£

ÑÛ¾¦½âÆÊ½á¹¹Í¼£¨Í¼Ô´google£©

¸ÃÑо¿ËѼ¯ÁË2009Äê7ÔÂÖÁ2010Äê8ÔÂÆÚ¼äÓ¡¶ÈÒ»ËùÒ½Ôº°¬×̲¡²¡¶¾¸ÐȾÖÐÐĵÄ321ÀýHIV/AIDS²¡Àý£¨642Ö»ÑÛ¾¦£©µÄÏà¹Ø²¡Ê·×ÊÁϲ¢½øÐÐÏàÓ¦µÄÑۿƼì²é¡£

321Àý²¡ÀýÖÐ87Àý³öÏÖÑÛ²¿Ö¢×´£¬ÆäÖÐ72.41%ΪÎÞÖ¢×´HIVЯ´øÕߣ¬¹Û²ìµ½µÄǰÆÏÌÑĤÑ×£¨P=0.004£©¡¢ºóÆÏÌÑĤÑ×£¨P=0.004£©ºÍHIV²¡±ä£¨P=0.048£©ÓëCD4+ TÁܰÍϸ°û¼ÆÊýÏÔÖøÏà¹Ø¡£ÑÛ²¿Ö¢×´µÄ×ÜÌ廼²¡ÂÊÒ²ÓëCD4+ TÁܰÍϸ°ûµÍ¼ÆÊýÏÔÖøÏà¹Ø£¨P£¼0.001£©¡£

²»Í¬ÑÛ²¿Ö¢×´»¼ÕßCD4+ TÁܰÍϸ°û¾ùÖµ

2 HIV³£¼ûÑÛ²¿²¢·¢Ö¢

³£¼ûµÄHIV¸ÐȾÑÛ²¿²¢·¢Ö¢

1 ·Ç¸ÐȾÐÔÑÛ²¿²¢·¢Ö¢

HIVÊÓÍøÄ¤²¡±ä£¨HIVR£©ÊÇ×î³£¼ûµÄ·Ç¸ÐȾÐÔÑÛ²¿²¢·¢Ö¢£¬·¢ÉúÂÊΪ50%~70%£¬ÌáʾѪ-ÊÓÍøÄ¤ÆÁÕÏµÄÆÆ»µ£¬±êÖ¾×ÅCD4+ TÁܰÍϸ°û¼ÆÊýϽµºÍ»ú»áÐÔ¸ÐȾ·çÏÕÔö¼Ó¡£µ¥***IVR¶ÔÊÓÁ¦Ó°ÏìС£¬µ«¿ÉÄܳöÏÖÉ«¾õÒì³£¡¢¶Ô±È¶ÈϽµµÈ£¬ÁÙ´²¼ì²é³£¼ûÃÞÈÞ°ß¡£

Õý³£ÑÛµ×£¨×ó£©ÃÞÈްߣ¨ÓÒ£©

HIVÏà¹ØÊÓÍøÄ¤ÊÓÉñ¾­Õϰ­£¨HIV-NRD£©ÔÚ»¼ÕßÖеķ¢ÉúÂÊΪ15%~16%£¬ÑÏÖØÓ°Ï컼ÕßµÄÊÓ¹¦ÄÜ£¬¿ÉÄÜÖÂ䣨ÊÓÁ¦µÍÓÚ0.1£©£¬ÉõÖÁËÀÍöÂÊÔö¼Ó¡£

ÊÓÎïÄ£ºý¡¢Á÷Àá¡¢ÒìÎï¸ÐµÈÖ¢×´³öÏÖ½ÏÕý³£È˶ࣨ74% vs. 46%£©£¬ÇÒ»á¼***Ù¸ÉÔïÐԽǽáĤÑ׺ÍÒí×´æÀÈâµÄ·¢Õ¹¡£

2 ¸ÐȾÐÔÑÛ²¿²¢·¢Ö¢

ÔÚHIV¸ÐȾÕߵĻú»áÐÔ¸ÐȾÖУ¬¾Þϸ°û²¡¶¾¸ÐȾÊǺܳ£¼û£¬ÆäÖоÞϸ°û²¡¶¾ÊÓÍøÄ¤Ñ×Êǰ¬×̲¡»¼Õß×î³£¼ûµÄCMV¸ÐȾ£¬·¢ÉúÂÊԼΪ10.5%£¬Ò²ÊÇAIDSÍíÆÚ×îÑÏÖØ¡¢×î³£¼ûµÄÑÛ²¿²¢·¢Ö¢¡£ÁÙ´²±íÏÖΪ¿ìËÙÊÓÁ¦Ï½µ£¬ÑÛµ×¼ì²é±íÏÖΪ¡°·¬Çѳ´¼¦µ°¡±Ñù¸Ä±ä£¬ÑØÑª¹Ü·Ö²¼µÄŨºñµÄ»Æ°×É«ÊÓÍøÄ¤ËðÉË¡£

¡°·¬Çѳ´¼¦µ°¡±Ñù¸Ä±ä

ÑÛ¹­ÐÎÌ岡·¢ÉúÂÊΪ1%~2%£¬ÓÈÆäµ±CD4+ T¡¢CD8+ TÁܰÍϸ°û¼ÆÊýµÍʱÈÝÒ×·¢²¡¡£µäÐͱíÏÖΪ»µËÀÐÔÊÓÍøÄ¤Ñס¢Éø³öÐÔÊÓÍøÄ¤ÂöÂçĤÑ×¼°²£Á§ÌåÑס£

Ë®¶»-´ø×´ðåÕ¶¾¸ÐȾ·¢²¡ÂÊ£¼1%£¬³£ÒýÆð¼±ÐÔÊÓÍøÄ¤»µËÀ×ÛºÏÖ¢£¨ÃâÒß¹¦ÄÜÊÜËð²»ÑÏÖØÊ±£©ºÍ½øÐÐÐÔÍâ²ãÊÓÍøÄ¤»µËÀ×ÛºÏÖ¢£¨ÃâÒß¹¦ÄܵÍÏÂʱ£©£¬»¼ÕßÓÐη¹â¡¢Á÷Àá¡¢ÑÛºìºÍÑÛǰºÚÓ°Æ®¶¯µÈÖ¢×´£¬ËæÖ®³öÏÖÊÓÁ¦¼±¾çϽµ¡£

÷¶¾ÂÝÐýÌå¸ÐȾͨ³£·¢ÉúÔÚHIV¸ÐȾµÄÔçÆÚ£¬ÑÛ²¿Ö¢×´ÊÇ÷¶¾ÂÝÐýÌå¸ÐȾµÄÑÏÖØ±íÏÖ¡£Ã·¶¾ÆÏÌÑĤÊÓÍøÄ¤Ñ×Ö÷ҪΪÊÓÍøÄ¤ÂöÂçĤÑ×ΪÖ÷£¬ÓÈÆäÊǶÔÓÚÌÇÆ¤Öʼ¤ËØÖÎÁÆÎÞЧÕߣ¬¸üÓ¦¸ß¶È»³Òɱ¾²¡¡£¡°ÎÞµäÐÍÌØÕ÷¡±ÊÇ÷¶¾¸ÐȾÔÚÑÛ²¿µÄÁÙ´²±íÏÖ×î´óµÄÌØµã£¬²¡¿ÉÒÔÔÚ÷¶¾¸ÐȾµÄÈκν׶γöÏÖ£¬¿ÉÒÔÀÛ»ýÑÛ²¿µÄÈκνṹ£¬×î³£¼ûΪȫÆÏÌÑĤÑס£

3 ÃâÒßÖØ½¨Ñ×ÐÔ·´Ó¦×ÛºÏÖ¢£¨IRIS£©

IRISÊôÓÚÑÏÖØµÄÑ×Ö¢·´Ó¦£¬ÓÈÆäÊǵ±CD4+ TÁܰÍϸ°û£¼50 cells/¦ÌLʱ½ÓÊÜHAARTÖÎÁÆ£¬ÃâÒß¹¦ÄÜѸËÙ»Ö¸´µÄÇé¿öÏÂIRISµÄ·çÏÕ¸ü¸ß¡£IRIS¶ÔÑÛ¾¦µÄ×÷ÓÿÉÄÜÊÇѸËÙ»Ö¸´µÄCD4+ TÁܰÍϸ°û¹¥»÷´æÔÚÓÚÊÓÍøÄ¤ÄÚµÄHIV²¡¶¾£¬²úÉúÑ×Ö¢·´Ó¦ÒýÆðµÄ¡£

A.IRIS»¼ÕßµÄÑÛǰ½Ú£¬¿É¼û½ÇĤºó½Ï¶à»Ò°×É«³ÁµíÎ·¿Ë®ÉÁ¹âÑôÐÔ£»B.²£Á§ÌåÑ×Ö¢ÐÔ»ì×ǵ¼ÖÂÑÛµ×Ä£ºý

3 ÖÎÁƺÍÔ¤·À

Ŀǰ¶ÔÓÚÑÛ²¿ºÏ²¢Ö¢×´µÄÖÎÁư¬×̲¡¼±ÐÔÆÚ£¬Ö¸ÄÏÉÐδÃ÷ȷͳһ˵Ã÷£¬½áºÏÖ¸ÄϺÍÏà¹ØÎÄÏ׸ÅÀ¨ÈçÏÂ

ÈçÖ¸ÄÏÍÆ¼öCMVRÖÎÁÆÊ¹ÓøüÎôÂåΤ5.0~7.5mg/kg£¬¾²ÂöµÎ×¢£¬Ã¿12Сʱ1´Î£¬14~21d£¬ºóÒÔ5mg/£¨kg¡¤d£©Ðò¹áά³ÖÖÎÁÆ¡£Ò²¿ÉʹÓÃ좼×ËáÄÆ180mg/£¨kg¡¤d£©·Ö2~3´ÎÓð¬×̲¡¼±ÐÔÆÚ£¬2~3Öܺó¸ÄΪ90mg/£¨kg¡¤d£©¾²ÂöµÎ×¢£¬1´Î/d¡£²¡ÇéÎ£ÖØÕß»òµ¥Ò»Ò©ÎïÖÎÁÆÎÞЧ¿É¶þÕßÁªÓá£CMVRÒ²¿ÉÇòºó×¢Éä¸üÎôÂåΤ¡£½¨ÒéÔÚ¿¹CMVÖÎÁÆ¿ªÊ¼2ÖÜÄÚ¾¡¿ìÆô¶¯HAART¡£

HIVÏà¹ØÑÛ²¿²¢·¢Ö¢½ÏÆäËûÆ÷¹ÙµÄ²¡±äÒþÄ䣬ÔÚÖÎÁƹý³ÌÖиüÐè¶à¼Ó×¢Ò⣬Ôö¼ÓÒÀ´ÓÐÔ£¬Î¬³ÖÁ¼ºÃµÄCD4+ TÁܰÍϸ°ûˮƽ£¬×¢Òâ±ÜÃâ»ú»áÐÔ¸ÐȾµÄ·¢Éú¡£

²Î¿¼ÎÄÏ×

1.Ambiya V , Sagar A , Patyal S , et al. Ocular manifestations in 321 male consecutive cases of human immunodeficiency virus infection/acquired immunodeficiency syndrome at an HIV-referral centre[J]. Medical Journal Armed Forces India, 2012, 68(3):214-221.

2.»ÆÈØ, »Æ»ÛæÂ, ÐÏâùÇÅ, et al. ÈËÀàÃâÒßȱÏݲ¡¶¾¸ÐȾµÄÑÛ²¿²¢·¢Ö¢[J]. ¹ú¼ÊÑÛ¿ÆÔÓÖ¾, 2018(8):1411-1415.

3.Visser L. HIV and the eye[J]. Continuing medical education, 2013, 31(4): 143-146.

4.ÖлªÒ½Ñ§»á¸ÐȾ²¡Ñ§·Ö»á°¬×̲¡±ûÐ͸ÎÑ×ѧ×é, Öйú¼²²¡Ô¤·ÀÓë¿ØÖÆÖÐÐÄ. Öйú°¬×̲¡ÕïÁÆÖ¸ÄÏ(2018°æ)[J]. ´«È¾²¡ÐÅÏ¢, 2018(6).

5.¶Å¿û·¼, ¹ù´¿¸Õ. °¬×̲¡Ïà¹ØÐÔÑ۵ײ¡[J]. ÖйúÒ½¿¯, 2018(8):854-857.

6.ÁõСΰ, Ò¶¿¡½Ü, ¹¢Ë¬, et al. ÈËÀàÃâÒßȱÏݲ¡¶¾¸ÐȾÕߺͻñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷»¼ÕßÑÛ²¿²¡±äÏà¹ØµÄ»ù´¡ÓëÁÙ´²Ñо¿[J]. ЭºÍҽѧÔÓÖ¾, 2016, 7(1):8-12.

ÍÆ ¼ö ÔÄ ¶Á

ÉÏÒ©ºó¸ÐȾ·´¶ø¸üÑÏÖØÁË£¬ÎªÊ²Ã´£¿

»¼ÕßÑÛÖеÄART£¬×îÔÚÒâµÄÊÇʲôָ±ê£¿

Copyright@2015-2025 www.xingbingw.cn ÐÔ²¡Íø°æ°åËùÓÐ